On Wednesday, the maker of Patanjali products,Divya Pharmacy was ordered to stop the production of medicines (BPgrit, Madhugrit, Thyrogrit, Lipidom and Eyegrit Gold tablets), falsely being promoted for the treatment of blood pressure, diabetes, goiter, glaucoma and high cholesterol by the Uttarakhand Ayurveda and Unani Licensing Authority.
Besides this, the authority has also asked Patanjali to submit revised formulation sheets and label claims for each of the five formulations for fresh approval of its products, citing “misleading advertisements”.
Divya Pharmacy can restart the production of these drugs only after getting approval for the revised indications from the health authority.
Earlier during July this year, a complaint was filed by Kerala-based ophthalmologist KV Babu.
This was the action taken in response to that complaint by the health authority.
Another complaint was sent to the State Licensing Authority (SLA) on October 11 through email by Babu.
In the meantime, in a letter sent to Divya Pharmacy, a copy of which is with HT, joint director and drug controller of the state health authority, Dr GCN Jangapangi has asked the pharmacy to remove “misleading and objectionable advertisements” from the media space with immediate effect and in future.
The letter read, “The company should publish advertisements that have been approved, else its manufacturing license would be...
Karnataka Deputy Chief Minister D K Shivakumar on Saturday rejected the claims of Congress MLAs from Tamil Nadu being shifted to a resort in Bengaluru post Assembly elections. He further said that ...